NASDAQ:COAG Hemab Therapeutics (COAG) Stock Price, News & Analysis $40.97 +0.86 (+2.14%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Hemab Therapeutics Stock (NASDAQ:COAG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hemab Therapeutics alerts:Sign Up Key Stats Today's Range$39.97▼$43.9850-Day Range$33.89▼$54.9452-Week Range$23.00▼$55.42Volume597,199 shsAverage Volume329,112 shsMarket Capitalization$1.91 billionP/E RatioN/ADividend YieldN/APrice Target$51.40Consensus RatingModerate Buy Company Overview Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious and underserved bleeding disorders. The company aims to create therapies that address limitations of existing approaches, including the need for frequent administration and the challenges associated with complex blood-product-based treatments. Its lead investigational program, HMB-001, is being developed for Glanzmann thrombasthenia, a rare inherited disorder in which platelets do not function properly and can cause severe bleeding. Hemab is also advancing additional research programs intended to address other rare bleeding and platelet disorders. Hemab Therapeutics was founded in 2018 and operates across Denmark and the United States. The company’s development programs are focused on advancing novel biologic medicines through clinical testing and, subject to regulatory approval, toward use in patients with significant unmet medical needs.AI Generated. May Contain Errors. Read More Hemab Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreCOAG MarketRank™: Hemab Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 220th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingHemab Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialHemab Therapeutics has a consensus price target of $51.40, representing about 23.4% upside from its current price of $41.67.Amount of Analyst CoverageHemab Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Hemab Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Hemab Therapeutics are expected to grow in the coming year, from ($3.09) to ($2.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hemab Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hemab Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.51% of the float of Hemab Therapeutics has been sold short.Short Interest Ratio / Days to CoverHemab Therapeutics has a short interest ratio ("days to cover") of 6.03.Change versus previous monthShort interest in Hemab Therapeutics has recently increased by 3.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHemab Therapeutics does not currently pay a dividend.Dividend GrowthHemab Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.89 News SentimentHemab Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Hemab Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for COAG on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows4 people have added Hemab Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $1,536,845.00 in company stock, which represents 0.0790% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Hemab Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,536,845.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsHemab Therapeutics has minimal institutional ownership at this time.Read more about Hemab Therapeutics' insider trading history. Receive COAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COAG Stock News HeadlinesHemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives $51.40 Consensus PT from BrokeragesSeptember 11, 2026 | americanbankingnews.comHemab Therapeutics (COAG) Stock Forecast & Price TargetAugust 14, 2026 | investing.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 16 at 1:00 AM | Paradigm Press (Ad)Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 12, 2026 | finance.yahoo.comHemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical CatalystsJuly 15, 2026 | seekingalpha.comHemab Therapeutics Presents Sustained Sutacimig Bleed Reduction Data and Preclinical Factor VII Deficiency Results at ISTH 2026July 14, 2026 | quiverquant.comQHemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 CongressJuly 14, 2026 | globenewswire.comHemab Advances Bleeding Disorder PipelineJuly 13, 2026 | benzinga.comSee More Headlines COAG Stock Analysis - Frequently Asked Questions How have COAG shares performed this year? Hemab Therapeutics' stock was trading at $34.00 on April 30, 2026. Since then, COAG stock has increased by 22.6% and is now trading at $41.67. How were Hemab Therapeutics' earnings last quarter? Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) announced its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.17. When did Hemab Therapeutics IPO? Hemab Therapeutics (COAG) raised $285 million in an initial public offering (IPO) on Friday, May 1st 2026. The company issued 16,750,000 shares at $16.00-$18.00 per share. When does the company's lock-up period expire? Hemab Therapeutics's lock-up period expires on Wednesday, October 28th. Hemab Therapeutics had issued 16,750,000 shares in its initial public offering on May 1st. The total size of the offering was $301,500,000 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period. Who are Hemab Therapeutics' major shareholders? Hemab Therapeutics' top institutional shareholders include Citadel Advisors LLC (1.12%), Braidwell LP (0.34%), Opaleye Management Inc. (0.10%) and The Manufacturers Life Insurance Company (0.04%). View institutional ownership trends. How do I buy shares of Hemab Therapeutics? Shares of COAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today9/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:COAG CIK2114044 Webwww.hemab.com Phone(452) 138-7627FaxN/AEmployees59Year Founded2019Price Target and Rating Average Price Target for Hemab Therapeutics$51.40 High Price Target$64.00 Low Price Target$36.00 Potential Upside/Downside+25.5%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio35.85 Quick Ratio35.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares46,712,000Free FloatN/AMarket Cap$1.91 billion OptionableN/A BetaN/A Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:COAG) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTSM just handed Trump's secretive AI project $100 billion — See this before September 29Taiwan Semiconductor just pledged another $100 billion to US chip manufacturing, bringing its total US investm...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemab Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemab Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
